<- Go Home
Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.
Market Cap
CHF 36.4B
Volume
966.5K
Cash and Equivalents
CHF 1.7B
EBITDA
CHF 1.9B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
CHF 5.3B
Profit Margin
47.50%
52 Week High
CHF 92.61
52 Week Low
CHF 54.12
Dividend
1.18%
Price / Book Value
3.87
Price / Earnings
40.20
Price / Tangible Book Value
-73.14
Enterprise Value
CHF 40.3B
Enterprise Value / EBITDA
20.47
Operating Income
CHF 1.4B
Return on Equity
10.42%
Return on Assets
4.31
Cash and Short Term Investments
CHF 1.7B
Debt
CHF 5.7B
Equity
CHF 9.4B
Revenue
CHF 11.2B
Unlevered FCF
CHF 1.1B
Sector
Pharmaceuticals
Category
N/A